VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company developing new technologies to expand vaccine protection in large, underserved markets. VBI's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic target viruses. The company’s leading eVLP asset is a preventative cytomegalovirus (CMV) vaccine; VBI has initiated GMP production of its CMV candidate for formal preclinical and Phase I trials. The company’s second platform is a thermostability technology that enables the development of vaccines and biologics capable of being stored or transported under fluctuating temperatures. VBI has completed proof-of-concept studies on the thermostability of several vaccines and biological targets. VBI is headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Canada.